<DOC>
	<DOCNO>NCT01239745</DOCNO>
	<brief_summary>This non-interventional study conduct several Eastern European country assess safety , tolerability efficacy Aromasin® administer real-word setting postmenopausal woman invasive estrogen receptor positive early breast cancer , disease-free completion 2 3 year tamoxifen continue treatment Aromasin® completion 5 year adjuvant hormonal therapy , understand Aromasin® use routine clinical practice , assess adherence prescribe Aromasin® treatment understand reason early discontinuation .</brief_summary>
	<brief_title>Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive , Estrogen Receptor Positive Early Breast Cancer</brief_title>
	<detailed_description>The study prematurely discontinue October 11 , 2011 due slow enrollment . It note safety concern see study factor decision .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal female , define one next : 1 . Natural menopause ≥1 year , 2 . Surgical ovariectomy , 3 . Chemotherapyinduced amenorrhoea ≥ 2 year . Patients surgical treatment histologically confirm breast cancer nonmetastatic time initial diagnosis . Patients diseasefree 2 3 year adjuvant tamoxifen treatment . Patients whose tumour estrogen receptor positive ( ER+ ) . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Patients Aromasin® treatment contraindicate ( see SmPC ) . Metastatic breast cancer contra lateral tumour . Other concomitant adjuvant endocrine therapy . Other concomitant antineoplastic treatment . Participation clinical trial investigational drug 30 day prior enrolment study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Hormone adjuvant treatment early breast cancer aromatase inhibitor follow 2-3 year tamoxifen</keyword>
</DOC>